摘要
目的评估骨转移去势抵抗性前列腺癌(CRPC)患者接受因卡膦酸二钠治疗的疗效和安全性。方法回顾性分析2020年3月至2022年12月在中山大学肿瘤防治中心接受因卡膦酸二钠治疗的骨转移CRPC患者的临床资料,评估患者治疗后的骨痛缓解情况、活动能力改善情况、骨相关事件发生情况以及不良反应发生情况。结果本研究共纳入68例患者,使用因卡膦酸二钠治疗的中位时间为12个月,用药后骨痛缓解有效率为55.9%,活动能力改善有效率为41.2%,治疗过程中有10.3%的患者出现骨相关事件。因卡膦酸二钠常见的不良反应有发热、乏力、骨骼肌疼痛和纳差等,均为1级或2级不良反应。结论因卡膦酸二钠治疗骨转移CRPC患者,初步结果显示其具有缓解骨痛、改善活动能力、降低骨相关事件的疗效,安全性较高且患者耐受性较好。
Objective To evaluate efficacy and safety of incadronnate disodium for the treatment of bone metastases in patients with castration-resistant prostate cancer.Methods Clinical data of patients with bone metastatic castration-resistant prostate cancer who received incadronnate disodium between March 2020 and December 2022 in our hospital were retrospectively analyzed.Bone pain remission rate,activity improvement rate,incidence rate of skeletal related events as well as adverse events rate were evaluated after treatment of incadronnate disodium.Results A total of 68 patients were included in this study.The median treatment duration of incadronnate disodium was 12 months,and the bone pain remission rate was 55.9%.The activity improvement rate was 41.2%,and skeletal related events occurred in 10.3%patients.The common adverse events included fever,weakness,myalgia and anorexia,which were all grade 1 or 2 events.Conclusions Preliminary results show that incadronnate disodium for the treatment of bone metastases in patients with castration-resistant prostate cancer can relieve bone pain,improve activity and reduce skeletal related events,so incadronnate disodium was safe and well tolerated in patients.
作者
杨振宇
龙星博
王骏
赵迪威
陈东
周芳坚
李永红
YANG Zhenyu;LONG Xingbo;WANG Jun;ZHAO Diwei;CHEN Dong;ZHOU Fangjian;LI Yonghong(Department of Urology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)
出处
《现代泌尿生殖肿瘤杂志》
2023年第5期286-289,共4页
Journal of Contemporary Urologic and Reproductive Oncology
